UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 287

Sortiert nach

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

Cancer science, 2022-05, Vol.113 (5), p.1731-1738

2022

Volltextzugriff (PDF)

Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

Pharmaceutics, 2021-10, Vol.13 (11), p.1748

2021

Volltextzugriff (PDF)

Management of bladder cancer in older patients

Japanese journal of clinical oncology, 2022-03, Vol.52 (3), p.203-213

2022

Volltextzugriff (PDF)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants

Cancer science, 2018-10, Vol.109 (10), p.3224-3234

2018

Volltextzugriff (PDF)

Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer

Cancers, 2022-11, Vol.14 (21), p.5425

2022

Volltextzugriff (PDF)

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Scientific reports, 2022-05, Vol.12 (1), p.8535-8535, Article 8535

2022

Volltextzugriff (PDF)

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7

JNCI : Journal of the National Cancer Institute, 2016-07, Vol.108 (7), p.djw005

2016

Volltextzugriff (PDF)

Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study

Japanese journal of clinical oncology, 2022-09, Vol.52 (9), p.1056-1061

2022

Volltextzugriff (PDF)

Impact of nerve sparing in robot‐assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence

International journal of urology, 2022-08, Vol.29 (8), p.824-829

2022

Volltextzugriff (PDF)

Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS‐JAPAN study

International journal of urology, 2022-11, Vol.29 (11), p.1271-1278

2022

Volltextzugriff (PDF)

Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin

Cancer science, 2010-05, Vol.101 (5), p.1177-1185

2010

Volltextzugriff (PDF)

Activated protein kinase C-alpha as a simple test for urothelial cancer screening

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16552-e16552

2022

Volltextzugriff (PDF)

High‐throughput screen identifies 5‐HT receptor as a modulator of AR and a therapeutic target for prostate cancer

The Prostate, 2020-08, Vol.80 (11), p.885-894

2020

Volltextzugriff (PDF)

Identification of Activated Protein Kinase Cα (PKCα) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer

International journal of molecular sciences, 2021-09, Vol.22 (17), p.9276

2021

Volltextzugriff (PDF)

Clinical advantages of robot‐assisted partial nephrectomy versus laparoscopic partial nephrectomy in terms of global and split renal functions: A propensity score‐matched comparative analysis

International journal of urology, 2021-06, Vol.28 (6), p.630-636

2021

Volltextzugriff (PDF)

Validation of models predicting lymph node involvement probability in patients with prostate cancer

International journal of urology, 2022-05, Vol.29 (5), p.428-434

2022

Volltextzugriff (PDF)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

International journal of urology, 2019-03, Vol.26 (3), p.426-428

2019

Volltextzugriff (PDF)

Immune‐related adverse events in urothelial cancer patients: Adjustment for immortal time bias

Cancer science, 2022-11, Vol.113 (11), p.3912-3921

2022

Volltextzugriff (PDF)

Perioperative therapies for urological cancers

Japanese journal of clinical oncology, 2020-04, Vol.50 (4), p.357-367

2020

Volltextzugriff (PDF)

Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer

International journal of urology, 2022-10, Vol.29 (10), p.1155-1162

2022

Volltextzugriff (PDF)

P300/CBP‐associated factor regulates Y‐box binding protein‐1 expression and promotes cancer cell growth, cancer invasion and drug resistance

Cancer science, 2010-08, Vol.101 (8), p.1797-1806

2010

Volltextzugriff (PDF)

Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer

Clinical cancer research, 2014-02, Vol.20 (4), p.951-961

2014

Volltextzugriff (PDF)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression

Cancer science, 2021-01, Vol.112 (1), p.323-330

2021

Volltextzugriff (PDF)

Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

The Journal of urology, 2019-12, Vol.202 (6), p.101097JU0000000000000422-1135

2019

Volltextzugriff (PDF)

1 – 25 von 287

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(269)
Mit Volltextzugriff
(243)

Publikationsform

Artikel
(285)
Berichte
(2)

Sprache

Englisch
(276)
Japanisch
(86)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials

Management of bladder cancer in older patients

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants

Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7

Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study

Impact of nerve sparing in robot‐assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence

Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS‐JAPAN study

Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin

Activated protein kinase C-alpha as a simple test for urothelial cancer screening

High‐throughput screen identifies 5‐HT receptor as a modulator of AR and a therapeutic target for prostate cancer

Identification of Activated Protein Kinase Cα (PKCα) in the Urine of Orthotopic Bladder Cancer Xenograft Model as a Potential Biomarker for the Diagnosis of Bladder Cancer

Clinical advantages of robot‐assisted partial nephrectomy versus laparoscopic partial nephrectomy in terms of global and split renal functions: A propensity score‐matched comparative analysis

Validation of models predicting lymph node involvement probability in patients with prostate cancer

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

Immune‐related adverse events in urothelial cancer patients: Adjustment for immortal time bias

Perioperative therapies for urological cancers

Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer

Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study

P300/CBP‐associated factor regulates Y‐box binding protein‐1 expression and promotes cancer cell growth, cancer invasion and drug resistance

Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression

Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Suchergebnisse filtern